STOCK TITAN

Telomir Pharmaceuticals (TELO) S-3 Filings

TELO NASDAQ

Here are the S-3 shelf registrations from Telomir Pharmaceuticals, Inc. (TELO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow TELO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELO filings page.

Rhea-AI Summary

Telomir Pharmaceuticals, Inc. (TELO) is registering 5,292,810 common shares for resale by selling securityholders: 4,900,750 outstanding shares and 392,060 shares issuable upon exercise of placement agent warrants. Holders may sell all, some or none after the registration statement becomes effective, at fixed, prevailing-market, market-related or negotiated prices. Telomir receives no resale proceeds, but may receive warrant exercise prices if warrants are exercised for cash.

The October 2026 private placement generated approximately $5.6 million in gross proceeds before placement agent fees and other offering expenses. Warrants generally require cash exercise, may be exercised cashlessly if no effective registration statement permits issuance or resale of the shares being exercised and those shares are not freely saleable under Rule 144 without volume or manner-of-sale limitations, and expire five years after issuance. The warrant ownership limit is 4.99%; holders may raise it by written notice to no more than 9.99%, with an increase effective on the 61st day after notice. Telomir is developing investigational Telomir-Zn; the FDA cleared its IND in April 2026 for advanced or metastatic TNBC, and the planned Phase 1/2 trial is expected to enroll approximately 76 patients.